The expected decline comes as Baxter’s Biopharma Solutions group reported $116m in sales for the second quarter, which represents a 6% decline. On a constant currency basis, however, the company reported a 2% sales increase driven by international demand from clients. The company did not respond to a request for comment.
Sales for the CMO business’ same quarter last year totaled $249m as the business saw delayed shipments and declining demand for about the last year. A spokesman told us that the $249m is an older figure "that is not restated for all the sales changes we made during the fourth quarter of 2014, including removing compounding and moving those sales to Baxter’s Integrated Pharmacy Solutions."
Baxter Biopharma Solutions offers both small and large molecule fill/finish and lyophilization services from US sites in Indiana, California and Illinois. Back in 2013, German facility gained additional capacity as the outsourcing of cytotoxic manufacturing increased.
The slow decline of Baxter’s CMO business comes as worldwide sales of the total company’s business hit $3.9bn -- a decline of 6% from the same quarter last year. Excluding the impact of foreign currency, worldwide sales grew 3%, exceeding the company’s guidance of 1%. By region, sales in the US grew 1% to $1.8bn, and international sales of $2.1bn represented a 12% decline.
On Tuesday morning, rare-disease drugmaker Shire offered to pay about $30bn for Baxter spin-off Baxalta, which would benefit from the lower tax rate of a UK-based company.